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Efficacy and safety of the metformin-mazindol anorectic 
combination in rat
The current study investigates the anorectic interaction and 
safety of the mazindol-metformin combination in rats. Iso-
bologram and interaction index were used to determine ano-
rectic interaction between mazindol and metformin in the 
sweetened milk model. The safety profile of the mazindol- 
-metformin combination was determined by measuring 
anxiety, blood pressure, hematic biometry and blood chem-
istry. An acute dose of mazindol and metformin adminis-
tered per os, individually or as a mixture, has reduced the 
milk consumption in rats in a dose-dependent manner. 
Theoretical effective dose 40 (ED40t) did not differ from the 
experimental effective dose 40 (ED40e) obtained with the 
mazindol-metformin mixture in the anorexia experiments, 
by Student s´ t-test. In addition, the interaction index con-
firmed the additive anorectic effect between both drugs. A 
single oral dose of ED40e mazindol-metformin mixture in-
duced anxiolysis in the elevated plus-maze test. Moreover, 
oral administration of mazindol-metformin combination for 
3 months significantly decreased glycemia, but not blood 
pressure nor other parameters of hematic biometry and 
blood chemistry. Results suggest that mazindol-metformin 
combination exerts an additive anorectic effect, as well as 
anxiolytic and hypoglycemic properties. Mazindol-metfor-
min combination might be useful in obese patients with 
anxiety disorders or diabetes risk factors.
Keywords: mazindol-metformin combination, anorectic in-
teraction, anxiolysis, hypoglycemic effect
Obesity, defined as abnormal or excessive fat accumulation, represents health risks 
and is recognized as a global epidemic. Obese patients have a higher risk of developing 
metabolic disorders such as dysmetabolic syndrome, diabetes mellitus and dyslipidemia, 
among others (1). In addition, there is a significant increase in the mortality rate if the body 
mass index is above 25 kg m–2 (2). On the contrary, it is well-accepted that a weight-loss of 
more than 3 % produces metabolic benefits in obese patients including diabetes preven-
tion, better insulin sensitivity and glucose control as well as improved dyslipidemia (1).
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Lifestyle interventions are considered first-line therapy for overweight and obese pa-
tients. They include a nutritional plan, increased physical activity and behavioral modifi-
cation techniques; however, most of the intensive lifestyle programs are difficult to follow 
under everyday conditions (1, 3). In addition, obesity bears a higher aetiological risk factor 
for developing diabetes mellitus than genetic, sex, diabetes family history, physical activ-
ity or dietary habits (4).
Pharmacotherapy used as an adjunct to lifestyle intervention enhances weight loss 
and maintains any loss for a longer period (1, 3). Multimodal therapy is a strategy recently 
used to treat obesity. Clinical evidence demonstrates that the combination of different 
medications with complementary mechanisms of action provides a greater body mass 
reduction with a better safety profile (5).
Metformin is the most widely used first-line drug for diabetes mellitus (1). It is a bigu-
anide that induces weight loss by anorectic effects as it inhibits the activity of AMP-acti-
vated protein kinase in the hypothalamic neurons (6). Metformin also improves sensitiv-
ity to insulin and leptin (6, 7) and increases levels of glucagon-like peptide 1 (8, 9). Despite 
the multiple mechanisms proposed to explain its anorectic effect, metformin prevents the 
onset of diabetes, but induces only a weak weight loss in patients with diabetes risk factors 
(10). Therefore, we suggest that the combination of metformin with other anorectic drugs 
could increase their anti-obesity effectiveness, which could have a positive impact on the 
reduction of diabetes risk.
Mazindol is an anorectic drug unrelated to β-phenylethylamines, so it does not share 
the side-effects, addiction potential and misuse of amphetamines. Its proposed mecha-
nism of action used to explain the anorectic effect is related to the stimulation of the cate-
cholaminergic system (11). Mazindol also inhibits the activity of glucose-responsive neu-
rons located in the lateral hypothalamus, resulting in decreased appetite and lowered 
gastric acid secretion (12). Furthermore, mazindol improves cholesterol, triglycerides and 
insulin levels (13, 14).
Based on the mentioned concerns, the current study was performed to investigate the 
anorectic interaction, metabolic improvement and the safety profile of the mazindol-met-
formin combination in rats.
EXPERIMENTAL
Animals
Male Wistar rats, 160–200 g, were used in the current study. Animals were obtained 
from the bioterium of the National Institute of Respiratory Diseases (Ciudad de México, 
México) and they were kept in polysulfone cages with free access to food (Laboratory Au-
toclavable Rodent Diet 5010, Lab Diet, USA) and water in a 12-hour light/dark cycle and at 
temperature 22–25 °C. The total number of animals was 126 and they were randomized in 
experimental groups which consisted of 6 rats each.
All experiments were performed in agreement with the requirements published in 
the Technical Specifications for the Production, Care and Use of Laboratory Animals 
(NOM-062-ZOO-1999, SAGARPA; México) and by National Research Council (US) Com-
mittee for the Update of the Guide for the Care and Use of Laboratory Animals (National 
Academies Press, 2011, Washington, DC). Moreover, the protocol was approved by the 
institutional ethics committee, INER/CI/397/18 (Number, B29-18).
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Drugs and treatments
Mazindol (purity of 99.8 %) and metformin (purity of 100 %) were provided by Pro-
ductos Medix S.A. de C.V. (CDMX, Mexico). Mazindol, metformin, or the mazindol-met-
formin combination were freshly suspended in the vehicle (a mixture of 90 % physiological 
saline and 10 % Tween 80) used in a volume of 4 mL kg–1 bm. Control group received only 
vehicle (4 mL kg–1 bm). Oral dosing of the vehicle and the drugs was done using a metal 
feeding curved needle (Model 7914, Cadene Science, USA).
Experiments were divided into acute (a single oral dose) and chronic (a daily oral dose 
for 90 days) procedures. In the acute procedures, vehicle, metformin (30–300 mg kg–1 bm), 
mazindol (1.7–30 mg kg–1 bm) or the theoretical total doses of mazindol-metformin (ED5t = 
13.9, ED10t = 27.8, ED20t = 55.5 and ED40t = 111.0 mg kg–1 bm) were orally administered 30 
minutes before the start of the anorexia test, whereas vehicle, metformin (208.9 mg kg–1 
bm), mazindol (13.2 mg kg–1 bm), or mazindol-metformin mixture (128.7 mg kg–1 bm) were 
orally administered just before the start of the anxiety test. In the chronic procedures, 
vehicle, metformin (208.9 mg kg–1 bm), mazindol (13.2 mg kg–1 bm), or the experimental 
total dose of mazindol-metformin (ED40e = 128.7 mg kg–1 bm) was orally administered once 
a day, at 10:00 a.m., for 90 days. Anxiety, cardiovascular variables and blood parameters 
were measured on days 30, 60 and 90, before daily drug administration. Body mass was 
recorded weekly before the daily drug administration.
Anorectic effect evaluation
To determine the anorectic effect of mazindol, metformin or their combination, the 
reduction of the sweetened milk intake was measured, as previously described by Cruz-
Álvarez et al. (15). Rats were habituated for 7 days to drink sweetened milk for 90 min. On 
the 8th day, 12-h fasted rats were orally administered the vehicle or increasing doses of 
mazindol (1.7–30 mg kg–1 bm), metformin (30–300 mg kg–1 bm) or mazindol-metformin 
mixture. The sweetened milk was offered to the rats and the total milk intake was mea-
sured after 1.5 h.
To prepare the sweetened milk, 1 L of boiled water was mixed with 100 g of powdered 
milk and 100 g of sucrose.
Safety profile evaluation
To compare the safety profile of mazindol, metformin or mazindol-metformin, the 
doses were fixed at 40 % of anorectic effect obtained experimentally (ED40e) for each drug 
treatment. 
Thus, the anxiolytic effect of oral mazindol (ED40e = 13.2 mg kg–1 bm), metformin (ED40e 
= 208.9 mg kg–1 bm) or mazindol-metformin (ED40e = 128.7 mg kg–1 bm), was evaluated us-
ing the elevated plus-maze model designated by Pellow and colleagues (16). The mazindol-
metformin mixture was tested at a fixed-ratio of 1:1 in order to have a high probability of 
identifying the anorectic interaction, if any.
Briefly, the plus-maze had two closed arms and two open arms connected by a central 
platform. The four arms are elevated 50 cm from the floor and separated 90° each from the 
other. To test the anxiolytic effect, rats were administered orally with vehicle or with any 
of the treatments described above and placed in the center of the platform with their head 
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facing one of the open arms. Then, free exploration was allowed for 5 min. During this 
period, the percentage of open arm entries and the percentage of time spent on the open 
arms were measured. The increase in the percentage of open arm entries and the percentage 
of time spent on the open arms is considered as an anxiolytic effect. In acute experiments, 
anxiety was evaluated in 12-h fasted rats before the treatment and at 1, 2, 3, 4, 6, and 8 h 
after a single oral dose administration. In chronic experiments, the drugs were given once 
a day for 3 months and the anxiety was measured in 12-h fasted rats before the drug 
 administration and at 1, 2 and 3 months, 24 h after the last administration.
In order to determine the chronic effect of the oral mazindol-metformin combination 
on body mass, the animals were administered daily with vehicle or mazindol-metformin 
(ED40e = 128.7 mg kg–1 bm), for 90 days. During this period, the body mass of the rats was 
recorded every week using an Ohaus Scout® balance H-7294 (Ohaus, Mexico).
In order to establish the cardiovascular effect of the chronic administration of the 
mazindol-metformin mixture, the blood pressure was measured in rats by a tail-cuff plethys-
mography blood pressure system (MRBP, IITC Life Sciences, USA). Animals were placed 
into an acrylic restrainer for 15 min during 3 consecutive days to allow them to adapt to 
the experimental conditions. The next day, rats were gently collocated inside the chamber 
for 15 min and baseline diastolic blood pressure and systolic blood pressure were acquired. 
After that, vehicle or mazindol (ED40e = 13.2 mg kg–1 bm), metformin (ED40e = 208.9 mg kg–1 
bm) or mazindol-metformin combination (ED40e = 128.7 mg kg–1 bm) were orally adminis-
tered daily during 3 months; diastolic and systolic blood pressure were recorded in 12-h 
fasted rats before the treatment and at 1, 2 and 3 months, 24 h after the last administration.
To check the health status of the rats after chronic administration of oral mazindol-
metformin combination (ED40e = 128.7 mg kg–1 bm), 500 µL of blood were taken from their 
lateral tail by a 23-gauge syringe needle, then the blood samples were tested in a BC7000 
hematology analyzer (Kontrolab, Italy) and a dry chemistry analyzer HB1 (Skyla, China). 
Parameters were measured in 12-h fasted rats before the treatment and at 1, 2 and 3 months, 
24 h after the last administration.
Data analysis
ED40e for mazindol and metformin were obtained from their respective log dose- 
- response curves by linear regression. ED40e was chosen for the interaction analysis of 
mazindol-metformin due to the fact that metformin was not able to reach an anorectic 
 effect of 50 % in the sweetened milk intake test (48.6 %).
To determine the type of interaction, theoretical effective doses of the combination 
were calculated using a fixed-dose ratio of 0.5: 0.5 and fractions of the ED40e for mazindol 
and metformin by the following equation:
EDxt = 0.5 (EDxe of mazindol) + 0.5 (EDxe of metformin)
where, x = 5, 10, 20 or 40 %. Thus, ED5t = 0.8 + 13.1 mg kg–1 bm, ED10t = 1.7 + 26.1 
mg kg–1 bm, ED20t = 3.3 + 52.2 mg kg–1 bm, and ED40t = 6.6 + 104.4 mg kg–1 bm, resp. Then, 
theoretical doses were tested in the sweetened milk intake test, and ED40e for mazindol-
metformin (7.7 + 121.0 mg kg–1 bm, resp.) was interpolated from its log dose-response curve 
obtained experimentally. The fixed-dose ratio of 0.5:0.5 was established to increase the 
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probability of identifying any anorectic interaction. For the sake of clarity, the doses for the 
combination are shown as the sum of mazindol and metformin doses throughout the text.
In order to analyze the type of interaction of mazindol-metformin, isobologram was 
constructed plotting the ED40e value of mazindol on the abscissa and the ED40e value of 
metformin on the ordinate. Later, a diagonal line connecting both ED40e values was traced 
to obtain the theoretical line of additivity; finally, either ED40e or ED40t for the combination 
were added within the isobologram.
To determine the type of interaction of mazindol-metformin theoretical effective dose 
40 (ED40t) and ED40e values were compared by Student’s t-test, as well as by the interaction 
index (γ = ED40e/ED40t), confidence intervals and isobologram plot (17, 18). The additivity 
between mazindol and metformin was established if ED40t was not different from ED40e by 
Student’s t-test, ED40t confidence interval overlapped the ED40e confidence interval, γ was 
close to 1, γ confidence interval crossed through 1 and ED40e was near to additivity line in 
the isobologram plot.
To determine the intensity and duration of anxiolytic effect with each treatment, the 
area under the curve (% open arm entries against time or % time spent on the open arms 
against time) was calculated by the trapezoidal rule. 
All statistical differences between treatments were obtained by one-way analysis of 
variance (ANOVA), followed by Dunnett`s test whereas differences with respect to the 
vehicle group, in time-course experiments, were analyzed by two-way ANOVA followed 
by Tukey s´ test. Experimental differences were statistically different if the p-value was less 
than 0.05.
All results are presented as the mean ± standard error of the mean (SEM) of 6 rats. 
RESULTS AND DISCUSSION
Anorectic effects of mazindol and metformin alone
The anorectic effect of mazindol, metformin and mazindol-metformin combination was 
assessed using the sweetened milk intake test. Increasing doses of acute oral administration 
of mazindol (1.7–30 mg kg–1 bm) dose-dependently reduced milk intake (Fig. 1a). Thus, 
Fig. 1. Anorectic effect of individual treatment with: a) mazindol and b) metformin. Given are means 
and SEM bars, n = 6. * Significant difference vs. vehicle group (Veh): p < 0.05.
a)                                                         b)
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mazindol had an anorectic efficacy of 52.1 ± 6.8 % at the dose of 30 mg kg–1 bm and an ED40e 
= 13.2 ± 2.8 mg kg–1 bm (Table I). Previous studies have pointed out that the mazindol treat-
ment was able to reduce the body mass increase and calorie intake in the models of ventro-
medial hypothalamic injured obese rats (14) and obese diabetic yellow KK mice (19). Concor-
dantly, several double-blind, placebo-controlled clinical studies indicated that mazindol is 
more effective than a placebo in achieving weight loss (11, 13). Moreover, a recent meta-
analysis confirmed that mazindol induced more weight loss than a placebo (20).
Also, metformin administered orally (30–300 mg kg–1 bm) had decreased the sweet-
ened milk consumption in a dose-dependent manner (Fig. 1b). According to the plot, met-
formin reached an anorectic effect of 48.6 ± 17.8 % at 300 mg kg–1 bm and it had an ED40e = 
208.9 ± 27.0 mg kg–1 bm (Table 1). In line with these results, metformin-induced weight loss 
in obese rats (21) and mice (22) and, decreased body mass in chickens (23). Moreover, a 
growing body of evidence demonstrates that metformin induces a modest weight loss in 
human beings (24–26). In this regard, the current study confirms the anorectic effect of 
mazindol and metformin individually in the sweetened milk intake test in rats.
Effect of mazindol-metformin combination on anorexia and body mass
To determine the anorectic interaction of mazindol and metformin in sweetened milk 
intake test, the ED5t = 13.9 mg kg–1 bm, ED10t = 27.8 mg kg–1 bm, ED20t = 55.5 mg kg–1 bm, and 
ED40t = 111.0 mg kg–1 bm were tested experimentally. The acute oral administration of 
mazindol-metformin reduced in a dose-dependent manner the sweetened milk consump-
tion reaching experimentally an anorectic effect of 40.0 ± 6.1 % at the highest tested dose. 
In addition, the linear regression analysis for the dose-response curve of the combination 
showed ED40e = 128.7 ± 25.0 mg kg–1 bm (Fig. 2a). Contrary to our results, Iorio et al. (27) 
indicated that amobarbital, diazepam, thioridazine and prochlorperazine did not affect 
the decrease in food consumption induced by mazindol. This difference may be due to the 
mechanism of action of the drugs used in combination with mazindol (GABAA agonism 
or D2 antagonism vs. inhibition of AMP-kinase).
In the interaction analysis, the ED40e (128.7 ± 25.0 mg kg–1 bm) of the mazindol-metfor-
min combination was not statistically different from ED40t (111.1 ± 13.6 mg kg–1) calculated 
for this combination (Table II), as is shown in the isobologram plot where the ED40e is very 
near to ED40t value (Fig. 2b). Concordantly, the ED40e confidence interval of the mazindol-
metformin overlapped with the theoretical ED40t confidence interval of this combination, 
the interaction index (γ) was around 1 and its confidence interval passed through 1 (Table 
II). In this regard, both, statistical and graphic analysis indicate that mazindol-metformin 
combination shows an additive anorectic effect in 12-h deprived rats. 
Table I. Experimental effective doses 40 (ED40e) of mazindol or metformin
Drug ED40e ± SEMa R2
Mazindol (mg kg–1 bm) 13.2 ± 2.8 0.953
Metformin (mg kg–1 bm) 208.9 ± 27.0 0.979
a n = 24.
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The additive anorectic effect of the mazindol-metformin combination may be under-
stood by the complementary mechanisms of both drugs. The mechanism of anorectic ac-
tion of mazindol probably includes the stimulation of catecholaminergic systems in the 
central nervous system, including dopamine (28), serotonin (29) and noradrenaline (30). 
Additionally, mazindol also seems to reduce the food intake through suppression of the 
firing rate of glucose-sensitive neurons in the lateral hypothalamus by a dopamine-inde-
pendent mechanism (12, 31). Moreover, it was suggested that mazindol may induce weight 
loss stimulating thermogenesis via increased noradrenaline turnover in the brown adipose 
tissue (19), inhibiting the gastric acid secretion (12) and absorption of glucose in the small 
intestine (32), increasing glucose uptake by the skeletal muscle (33) and reducing hyper-
secretion of insulin from the ventromedial hypothalamic area (14). In a complementary 
manner, metformin induces anorexia by inhibition of ghrelin-induced hypothalamic 
AMP-kinase/acetyl-CoA carboxylase/regulatory-associated protein of mTOR signaling 
(34). It also seems to down-regulate orexigenic peptides as agouti-related protein or neuro-
peptide Y and, increase anorexigenic peptides as pro-opiomelanocortin, in the hypothalamus, 
through STAT3 signaling pathway (35). Furthermore, it has been demonstrated that met-
formin improves the sensitivity to leptin and insulin, two hormones capable of modulating 
AMP-kinase and STAT3 in the hypothalamus, to produce anorexia (6, 34). Alike, metformin 
Table II. Statistical analysis of mazindol-metformin combination
Mazindol-metformin combination
(mg kg–1 bm) γ ± SEM
(CI at 90 %)aTheoretical
ED40t ± SEM (CI at 90 %)a
Experimental







a n = 24.
Fig. 2. a) Anorectic effect and b) isobolographic analysis of the combination mazindol + metformin in 
12-h fasted rats. Given are means and SEM bars, n = 6. * Significant difference vs. vehicle group (Veh): 
p < 0.05. ED40t (●) – theoretical effective dose for 40 % effect, ED40e (○) – experimental effective dose for 
40 % effect.
a)                                                            b)
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enhances glucagon-like peptide-1 level to induce satiation, through the inhibition of di-
peptidyl peptidase-IV, an enzyme that degrades importantly to glucagon-like peptide-1 (8) 
and the activation of muscarinic and gastrin-releasing peptide pathways (9). The current 
data seems to indicate that mazindol-metformin combination may be achieved, due to 
their complementary mechanisms of action on the regulation of food intake, in lower doses 
of each drug, thus demonstrating additive action with a reduction of dose-related adverse 
events.
In addition, chronic administration of mazindol-metformin (ED40e = 128.7 mg kg–1 bm) 
for 90 days significantly decreased the body mass in rats from week 6 onwards in respect 
to the vehicle group, but not mazindol (ED40e = 13.2 mg kg–1 bm) or metformin (ED40e = 208.9 
mg kg–1 bm) groups (Fig. 3). Thus, the current study demonstrates for the first time that 
mazindol-metformin combination has an additive anorectic effect, which in turn impacts 
the body mass.
Safety profile of the mazindol-metformin combination
Fig. 4 shows that a single dose of ED40e of mazindol (13.2 mg kg–1 bm), but not ED40e of 
metformin (208.9 mg kg–1 bm), enhanced significantly the time spent in the open arms (Figs. 
4a,b) and open arm entries (Figs. 4c,d) in comparison to the vehicle group, in 12-h food-
deprived rats. Interestingly, in the mazindol-metformin group (ED40e = 128.7 mg kg–1 bm), 
metformin was able to maintain the anxiolytic effect of mazindol with approximately the 
half of the mazindol dose used individually (Fig. 4). This finding seems to demonstrate for 
the first time the anxiolytic effect of mazindol, but this should be confirmed in other anxio-
lytic models since the plus-maze model loses predictive validity in the evaluation of drugs 
that act by mechanisms which do not include GABAergic system (36). Thus, the apparent 
anxiolytic effect could be also explained by an increase in motor activity induced by 
mazindol (37). The results of the current study allow us to suggest that mazindol-metformin 
combination may be directed to obese patients with anxiety disorders due to the fact that 
there is a positive association between obesity and anxiety (38) and, the prevalence of 
 anxiety disorders as binge eating disorder in overweight patients is around 20 % (39).
Fig. 3. ED40e of mazindol (13.2 mg kg–1 bm), metformin (208.9 mg kg–1 bm) or mazindol-metformin 
combination (128.7 mg kg–1 bm) on body mass. Given are means and SEM bars, n = 6. * Significant 
difference vs. vehicle group, p < 0.05.
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Oral administration for 90 days of mazindol, metformin or mazindol-metformin com-
bination did not change significantly diastolic or systolic blood pressure. Likewise, blood 
cell and red blood cell count remained constant throughout the pharmacological treat-
ment. On the contrary, glucose level, but not other blood chemistry parameters, was re-
duced from 5.6 ± 0.4 to 5.0 ± 0.5 mmol L–1, and 5.6 ± 0.5 to 4.6 ± 0.6 mmol L–1 after 3 months 
of the chronic metformin alone (data not shown) or mazindol-metformin combination 
(Table III) treatment, resp. These data suggested a good tolerability profile of the combina-
tion and seems to show that mazindol enhances the glycemic control induced by metfor-
min. Taking in consideration that obesity is the strongest aetiological risk factor for deve-
loping type 2 diabetes (4) and that metformin is considered as a suitable candidate for 
diabetes prophylaxis, but with the disadvantage of a weak clinical weight-reduction (1), we 
suggest that mazindol-metformin combination may be especially useful as weight loss 
medication in obese patients with diabetes risk factors because of its anorectic and hypo-
glycemic effects. In line with the current results, the literature showed that metformin 
reduces the incidence of persons at high risk for diabetes mellitus (40) and mazindol 
 reduces the blood glucose and insulin concentrations in mice (19).
Moreover, in the current study, acute administration of mazindol, but not metformin, 
showed mild piloerection, stereotyped movements of head and forepaws and walking in 
circles (data not shown), at the highest dose tested, indicating disturbances at the central 
nervous system level. These adverse events are in line with a previous study where the 
Fig. 4. The anxiolytic effect of ED40e of mazindol (13.2 mg kg–1 bm), metformin (208.9 mg kg–1 bm) and 
mazindol-metformin mixture (128.7 mg kg–1 bm) in the plus maze task. Given are means and SEM 
bars, n = 6. * Significant difference vs. vehicle group, p < 0.05.
a)                                                                 b)
c)                                                                 d)
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0 1 2 3
Blood chemistrya
Albumin (g L–1) 37.7 ± 4.6 37.3 ± 2.0 41.0 ± 2.0 41.4 ± 2.1
Globulins (g L–1) 23.2 ± 8.7 20.5 ± 4.6 21.7 ± 2.5 22.6 ± 2.2
Total protein (g L–1) 60.9 ± 12.7 57.8 ± 5.5 62.7 ± 4.1 64.0 ± 2.6
Glucose (mmol L–1) 5.6 ± 0.5 4.8 ± 0.6 4.7 ± 0.5* 4.6 ± 0.6*
Alkaline phosphatase (U L–1) 191.7 ± 55.6 211.3 ± 52.5 175.3 ± 55.8 189.4 ± 51.5
Alkaline aminotransferase (U L–1) 34.3 ± 3.4 40.3 ± 4.6 36.8 ± 5.7 36.4 ± 5.7
Amylase (U L–1) 166.5 ± 27.8 158.5 ± 19.5 184.5 ± 18.1 173.2 ± 21.7
Uremic nitrogen (mmol L–1) 6.2 ± 0.8 6.3 ± 0.5 6.5 ± 0.5 6.2 ± 0.5
Creatinine (µmol L–1) 31.7 ± 5.2 34.0 ± 8.3 36.2 ± 10.2 33.4 ± 7.4
Calcium (mmol L–1) 2.02 ± 0.22 2.07 ± 0.12 2.23 ± 0.13 2.16 ± 0.06
Phosphate (mmol L–1) 1.86 ± 0.10 1.90 ± 0.14 1.76 ± 0.21 1.80 ± 0.07
Sodium (mmol L–1) 153.7 ± 2.4 155.2 ± 1.9 151.8 ± 2.9 154.0 ± 2.0
Potassium (mmol L–1) 6.3 ± 0.2 6.7 ± 0.5 6.4 ± 0.3 6.4 ± 0.3
Hematic biometrya
White blood cells (×109 cells L–1) 6.5 ± 1.5 6.6 ± 1.3 6.6 ± 0.9 6.7 ± 0.7
Lymphocytes (×109 cells L–1) 1.0 ± 0.5 0.8 ± 0.2 0.8 ± 0.2 1.0 ± 0.2
Monocytes (×109 cells L–1) 3.0 ± 0.5 3.3 ± 0.6 3.5 ± 0.4 3.3 ± 0.5
Granulocytes (×109 cells L–1) 2.4 ± 0.7 2.6 ± 0.7 2.3 ± 0.5 2.4 ± 0.5
Red blood cells (×1012 cells L–1) 8.0 ± 0.7 8.1 ± 0.7 8.1 ± 0.6 8.0 ± 0.4
Hemoglobin (g L–1) 122.0 ± 8.3 125.5 ± 7.9 126.8 ± 10.0 124.8 ± 7.3
Hematocrit (%) 48.4 ± 4.2 51.9 ± 3.7 52.5 ± 4.6 51.9 ± 1.9
Platelets (×109 cells L–1) 338.8 ± 57.2 279.5 ± 61.6 297.0 ± 61.1 296.2 ± 45.0
Mean platelet volume (fL) 15.00 ± 0.82 15.85 ± 0.80 15.70 ± 0.61 15.34 ± 0.54
Plateletcrit (%) 0.45 ± 0.08 0.43 ± 0.07 0.46 ± 0.08 0.42 ± 0.07
Blood pressurea
Systolic blood pressure (mm Hg) 119.4 ± 1.3 117.4 ± 1.3 120.2 ± 3.5 122.3 ± 2.1
Diastolic blood pressure (mm Hg) 91.0 ± 0.5 97.8 ± 3.5 90.8 ± 1.1 92.3 ± 1.2
a Mean ± SEM, n = 6.
* Significant difference vs. basal value (time 0): p < 0.05.
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authors showed that mazindol triggers stereotyped behaviors as sniffing, licking and false 
bites (37). Importantly, the mazindol-metformin combination did not show such effects 
confirming that metformin improves the mazindol safety profile.
CONCLUSIONS
The results suggest that mazindol-metformin combination shows an additive anorectic 
effect, as well as hypoglycemic and anxiolytic properties, with a good safety profile. Thus, 
mazindol-metformin may be a therapeutic option as initial treatment for obesity in pa-
tients with diabetes risk factors and/or anxiety disorders, which deserves to be further 
studied in clinical trials.
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